Art Unit 1638

Group 1630Stem Cells and Nucleic Acid Related Therapy

Active examiners
33
Average office actions per grant
1.45

Grant ratio

Art Unit 1638
70.8%
Group 1630
52.0%

Active examiners

Brent T Page 82.2% 1.44 August 2026
Medina A. Ibrahim 83.2% 1.35 August 2026
Cynthia Collins 82.4% 1.30 August 2026
Cathy Kingdon Worley 80.0% 1.38 August 2026
David H. Kruse, Ph.D 81.8% 1.49 August 2026
Anne R. Kubelik, Ph.D 76.9% 1.58 August 2026
Li Zheng 79.5% 1.54 August 2026
Vinod Kumar 73.5% 1.19 August 2026
Phuong T Bui 76.2% 1.41 August 2026
Russell Kallis 88.0% 1.26 June 2026
Michael C Wilson 34.8% 2.83 August 2026
Michael Burkhart 47.1% 1.95 August 2026
Kevin K. Hill 22.3% 2.40 July 2026
Robert M Kelly 48.9% 1.97 August 2026
Keith O. Robinson 70.6% 1.14 August 2026
Eric J Rogers 30.5% 1.85 August 2026
Lauren K Van Buren 20.8% 3.34 August 2026
Thomas Russe Amick 36.6% 2.28 August 2026
John David Moore 22.5% 1.35 August 2026
Fatimah Khalaf Matalkah 12.8% 1.30 August 2026
Allison M Johnson 15.8% 1.75 August 2026
Catherine L Mccormick 6.7% 1.00 August 2026
Hanna M Thueson 1.7% 1.00 August 2026
Matthew R Keogh 57.4% 1.71 August 2026
Jason Deveau-Rosen 52.8% 1.65 August 2026
Russell T Boggs 53.1% 1.70 August 2026
Mykola V Kovalenko 58.3% 1.76 August 2026
Rebecca Stephens 41.7% 1.84 August 2026
Tracy Vivlemore 77.3% 1.58 August 2026
Walter Jackson Iii 0.0% N/A August 2026
Adam M Smith 0.0% N/A August 2026
Vyoma Shubham Tiwari 33.3% 2.43 August 2026
Alexandra Connors 17.6% 3.14 August 2026

Examiner distribution

Median grant ratio
50.9%
Middle 50% of grant ratios
22.4%–77.0%
Median office actions / grant
1.58
Middle 50% of office actions / grant
1.35–1.85

Active examiners with at least 20 applications.

Other associated examiners

Examiners without recent activity.

Based on available public USPTO records; may be incomplete.

Job History

These are temporarily preserved for your convenience, but expire quickly for your security. We never save substantive inputs, pasted text, and/or uploaded files.

Jobs will appear here.